Market research
GE9.F Genmab A/S
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 14B
- P/E ratio
- 58.08
- Analyst target
- 480.81
- Dividend yield
- Not available
- Beta
- 0.69
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- DK0010272202
- Market cap
- 14B
- P/E ratio
- 58.08
- Analyst target
- 480.81
- Dividend yield
- Not available
- Beta
- 0.69
About
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GE9.F discussion.
5 years, 5 months ago
Genmab A/S is currently in a long term uptrend where the price is trading 12.7% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the sector with a price to sales ratio of 0.0.
Genmab A/S's total revenue sank by 0.0% to $3B since the same quarter in the previous year.
Its net income has dropped by 0.0% to $1B since the same quarter in the previous year.
Finally, its free cash flow fell by 653.5% to $-856M since the same quarter in the previous year.
Based on the above factors, Genmab A/S gets an overall score of 2/5.